You are here

  • Home
  • Online First
  • Treatment of asymptomatic chlamydia and gonorrhoea drives antibiotic consumption in PrEP cohorts

Article Text

Article menu
Download PDFPDF
Letter
Treatment of asymptomatic chlamydia and gonorrhoea drives antibiotic consumption in PrEP cohorts
  1. Thibaut Vanbaelen1,
  2. Sheeba Santhini Manoharan-Basil2,3,
  3. Chris Kenyon2
  1. 1Department of Clinical Sciences, Institute of Tropical Medicine, Antwerpen, Belgium
  2. 2Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  3. 3ITG, Institute of Tropical Medicine, Antwerpen, Belgium
  1. Correspondence to Dr Chris Kenyon; ckenyon{at}itg.be

https://doi.org/10.1136/sextrans-2024-056381

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Excessive consumption of antimicrobials drives antimicrobial resistance (AMR).1 The frequent emergence of AMR in subpopulations of men who have sex with men (MSM), such as HIV pre-exposure prophylaxis (PrEP) cohorts, has been linked to high consumption of antimicrobials.2 Reducing antimicrobial consumption requires knowledge of what drives this consumption. In the current study, we therefore describe this breakdown using data from the recently published Gonoscreen study.3 This was the first randomised controlled trial in MSM to assess if no-screening was non-inferior to 3-site (pharyngeal, anal and urethral), 3-monthly screening (3X3 screening) for Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct) in terms of the cumulative incidence of these infections.3 We report the indications for antimicrobial use from the 506 individuals in the 3X3 screening arm who were followed up every 3 months for 12 months. Detailed consumption data …

    View Full Text

    Footnotes

    • Handling editor Anna Maria Geretti

    • Contributors CK conducted the analyses and wrote a first draft. CK, TV and SB contributed to the final draft.

    • Funding Belgian Healthcare Knowledge Center (KCE - INV18-1133)

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.